Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced …Read more »
- Alligator to attend and present at the at the DNB Small and Medium Enterprises (SME) Conference in OsloApril 5, 2017
- PEGS, BostonMay 1, 2017 - May 5, 2017
- Annual General MeetingMay 2, 2017
Alligator Bioscience has a broad project portfolio with several antibody-based pharmaceuticals in immuno-oncology. Several of these R&D projects are operated in-house. The company's most advanced project, ADC-1013, is in clinical Phase I and is being developed together with partner Janssen Biotech.